• Subjects must have signed and dated an Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved written informed consent form (ICF) in accordance with regulatory and institutional guidelines.

• At least 18 years and no older than 70 years at the time of signing the ICF.

• 18 kg/m2 ≤ body mass index (BMI) ≤ 30 kg/m2 and 50 kg ≤ body weight ≤ 85 kg.

• The patient with one of the following resected solid tumors:

‣ Stage IB (T2a ≥ 4 cm), II, or IIIA NSCLC patients after complete resection OR

⁃ Stage IIB, IIC, or III melanoma following complete resection OR

⁃ Renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

• Have a performance status of 0 on the Eastern Cooperative Oncology Group (ECOG) Performance Status within 7 days prior to the first dose in this study.

• Have a life expectancy of at least 12 weeks.

• Have adequate organ function as indicated by the following laboratory values (no blood transfusions, or treatment with albumin, recombinant human thrombopoietin or colony-stimulating factor within 14 days prior to the first dose in this study)

• Female patients must meet one of the following conditions:

∙ Menopause (defined as no menstruation for at least 1 year with no confirmed cause other than menopause), or

‣ Surgically sterilized (removal of the ovaries and/or uterus), or

‣ Fertile, but must:

⁃ be tested negative for serum/urine pregnancy test within 7 days prior to the randomization, and

• agree to use contraception methods with an annual failure rate of \< 1% or to remain abstinent (avoid heterosexual intercourse from signing the ICF to at least 6 months after the last dose of the study drug) (a contraceptive method with an annual failure rate of \< 1% includes bilateral tubal ligation, male sterilization, correct use of hormonal contraceptives that can inhibit ovulation, hormone-releasing intrauterine devices and copper-containing intrauterine devices or condoms), and

• not breastfeed

• Male patients must: agree to remain abstinent (avoid heterosexual intercourse) or take contraception measures as follows: male patients with a pregnant partner or a partner of childbearing potential must remain abstinent or use condoms to prevent drug exposure to the embryo during study treatment and for at least 6 months after the last dose of study drug. Periodic abstinence (e.g., contraception based on calendar day, ovulatory phase, basal body temperature, or postovulatory phase) and external ejaculation are ineligible methods of contraception.